PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 636545

Active specific immunotherapy of human solid tumors.

F E Rosato·E Miller·E F Rosato
View original source ↗Export metadata ↓

Abstract

A limited study of tumor patients with otherwise untreatable lesions suggests the feasibility of using enzyme altered cells in the active specific immunotherapy of human solid tumors.

Explore related subjects

AdenocarcinomaBreast NeoplasmsColonic NeoplasmsFemaleGenital Neoplasms, FemaleHumansImmunotherapyLymphatic MetastasisNeoplasmsSkin NeoplasmsStomach NeoplasmsJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

F E Rosato, E Miller, E F Rosato. 1978. Active specific immunotherapy of human solid tumors.. https://pubmed.ncbi.nlm.nih.gov/636545/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2001

Interaction of Galpha 12 and Galpha 13 with the cytoplasmic domain of cadherin provides a mechanism for beta -catenin release.

The G12 subfamily of heterotrimeric G proteins, comprised of the alpha-subunits Galpha12 and Galpha13, has been implicated as a signaling component in cellular processes ranging from cytoskeletal changes to cell growth and oncogenesis. In an attempt to elucidate specific roles of this subfamily in cell regulation, we sought to identify molecular targets of Galpha12. Here we show a specific interaction between the G12 subfamily and the cytoplasmic tails of several members of the cadherin family of cell-surface adhesion proteins. Galpha12 or Galpha13 binding causes dissociation of the transcriptional activator beta-catenin from cadherins. Furthermore, in cells lacking the adenomatous polyposis coli protein required for beta-catenin degradation, expression of mutationally activated Galpha12 or Galpha13 causes an increase in beta-catenin-mediated transcriptional activation. These findings provide a potential molecular mechanism for the previously reported cellular transforming ability of the G12 subfamily and reveal a link between heterotrimeric G proteins and cellular processes controlling growth and differentiation.

Adenocarcinoma↗
PubMed1992

[Radical prostatectomy--experience with 50 patients].

Between 1986-1991 we treated 50 men with adenocarcinoma of the prostate by radical prostatectomy. Ages ranged from 44-74 and clinical stages were A-C. Follow-up lasted 1-63 months (mean 15.1) and was designed to rule out recurrence and/or spread of the disease and to evaluate quality of life. The rate of complications was low, the postoperative course short and uneventful, and there was preservation of urinary continence in 96% and of potency in 10.2%. As compared with radiotherapy, surgery gave superior results and is recommended.

Adenocarcinoma↗
PubMed1992

Comparison of computed tomography and radiography for detecting changes induced by malignant nasal neoplasia in dogs.

The ability of computed tomography and radiography to detect changes associated with nasal neoplasia was compared in dogs. Eighteen areas or anatomic structures were evaluated in 21 dogs for changes indicative of neoplasia. Computed tomography was superior (P < or = 0.05) to radiography for detecting changes in 14 of 18 areas. Radiography was not superior for detecting changes in any structure or area. Computed tomography reveals vital information not always detected radiographically to assist in providing a prognosis and in planning treatment for nasal neoplasms in dogs.

Adenocarcinoma↗